

Stryker Corporation Announces Pricing of \$1.0 Billion Senior Notes Offering

March 20, 2013 4:21 PM ET

Stryker Corporation (NYSE:SYK) announced today that it has priced an offering to sell \$600 million of senior unsecured notes due 2018 (the "2018 Notes") and \$400 million of senior unsecured notes due 2043 (the "2043 Notes"). The 2018 Notes will bear interest at 1.300% per year and, unless previously redeemed, will mature on April 1, 2018. The 2043 Notes will bear interest at 4.100% per year and, unless previously redeemed, will mature on April 1, 2043.

The Company intends to use the net proceeds from the offering for working capital and other general corporate purposes, including acquisitions, stock repurchases and other business opportunities.

Barclays, BofA Merrill Lynch, and Goldman Sachs are acting as active joint book-running managers for the offering. This offering was made pursuant to a prospectus supplement to the Company's prospectus, dated February 28, 2013, filed as part of the Company's effective shelf registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the notes may be obtained by contacting the joint book-running managers: Barclays Capital Inc., Attention: Prospectus Department, 745 Seventh Avenue, New York, New York 102825, or by calling 888-603-5847, or by emailing barclaysprospectus@broadridge.com; Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, or by calling 866-471-2526, or by emailing prospectus-ny@ny.email.gs.com; and Merrill Lynch, Pierce, Fenner & Smith Incorporated, Attention: Prospectus Department, 222 Broadway, 11th Floor, New York, New York 10038, or by calling 800-294-1322, or by emailing Dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

This press release contains information that includes or is based on forward-looking statements within the meaning of the federal securities law that are subject to various risks and uncertainties that could cause our actual results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally, including cost-containment measures that could adversely affect the price of or demand for our products; changes in foreign exchange markets; legislative and regulatory actions; unanticipated issues arising in connection with clinical studies and otherwise that affect U.S. Food and Drug Administration approval of new products; changes in reimbursement levels from third-party payors; a significant increase in product liability claims; the ultimate total cost with respect to the Rejuvenate and ABG II matter; the impact of investigative and legal proceedings and compliance risks; resolution of tax audits; the impact of the federal legislation to reform the United States healthcare system and the 2.3 percent medical device excise tax; changes in financial markets; changes in the competitive environment; our ability to integrate acquisitions, including the acquisition of Trauson Holdings Company Limited; and our ability to realize anticipated cost savings as a result of workforce reductions and other restructuring activities. Additional information concerning these and other factors are contained in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Stryker is one of the world's leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care. The Company offers a diverse array of innovative medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products to help people lead more active and more satisfying lives.

Contacts

For media inquiries please contact:

Yin Becker, Stryker Corporation, 201-831-5000 or yin.becker@stryker.com

For investor inquiries please contact:

Katherine A. Owen, Stryker Corporation, 269-385-2600 or katherine.owen@stryker.com

HUG#1686903